

LISTING OF CLAIMS

1. (Currently amended) An immunoconjugate protein comprising:
an Fc ~~region~~ domain of a human IgG1 immunoglobulin, conjugated to a targeting domain comprising a mutant form of factor VII comprising one or two mutations selected from the group consisting of: a substitution of alanine for lysine-341, and a substitution of alanine for serine-344, wherein the immunoconjugate protein binds to tissue factor.
2. (Previously presented) An immunoconjugate according to claim 1 wherein the targeting domain comprises human factor VII having a substitution of alanine for lysine-341.
3. (Previously presented) An immunoconjugate according to claim 1 wherein the targeting domain of the immunoconjugate protein comprises human factor VII having a substitution of alanine for serine-344.
4. (Canceled)
5. (Canceled)
- 4, ~~5~~. (Previously presented) An immunoconjugate according to claim 1 wherein the immunoconjugate protein is made by the process of culturing a cell which comprises an expression vector which encodes the immunoconjugate.
- 5, ~~6~~. (Previously presented) An immunoconjugate according to claim ~~5~~⁴ wherein the expression vector is a replication-deficient adenoviral vector.
- 6, ~~7~~. (Previously presented) An immunoconjugate according to claim ~~6~~⁴ wherein the expression vector is an adeno-associated expression vector.
9. (Withdrawn) A method for treating a disease associated with neovascularization, which comprises administering to a patient having the disease an effective amount of an immunoconjugate protein according to claim 1.

10. (Withdrawn) A method according to claim 9 wherein the targeting domain of the immunoconjugate protein comprises human factor VII having a substitution of alanine for lysine-341.

11. (Withdrawn) A method according to claim 9 wherein the targeting domain of the immunoconjugate protein comprises human factor VII having a substitution of alanine for serine-344.

12. (Withdrawn) A method according to claim 9 wherein a second immunoconjugate protein having an effector domain which is the Fc ~~region~~ domain of an IgG1 immunoglobulin conjugated to a targeting domain which is a human scFv or V_H antibody fragment that binds to neovasculature or to tumor cells is administered to the patient as adjunct therapy.

13. (Withdrawn) A method according to claim 9 wherein the disease is cancer involving a vascularized tumor.

14. (Withdrawn) A method according to claim 9 wherein the patient is treated by administration of the immunoconjugate protein in a pharmaceutically acceptable carrier.

15. (Canceled)

16. (Canceled)

17. (Withdrawn) A method for treating cancer in a patient, which comprises administering to the patient an effective amount of at least one type of immunoconjugate protein comprising the Fc ~~region~~ domain of a human IgG1 immunoglobulin conjugated to a targeting domain comprising a mutant form of human factor VII selected from the group consisting of native factor VII having a substitution of alanine for lysine-341, native factor VII having a substitution of alanine for serine-344, and native factor VII having a substitution of alanine for lysine-341 and for serine-344, wherein the immunoconjugate protein binds to tissue factor.

18. (Withdrawn) A method according to claim 17 wherein a second immunoconjugate protein having an effector domain which is the Fc ~~region~~ domain of a human IgG1 immunoglobulin conjugated to a targeting domain which is a human scFv or V_H antibody fragment that binds to the patient's type of tumor cell is administered to the patient as adjunct therapy.

19. (Withdrawn) A method according to claim 17 wherein the patient is treated by administering the immunoconjugate in a pharmaceutically acceptable carrier.

20. (Cancelled)

21. (Currently amended) An immunoconjugate according to claim 1 wherein the immunoconjugate protein forms a dimer of two identical chains, each having ~~said an effector domain~~ said Fc domain of a human IgG1 immunoglobulin and ~~a~~ said targeting domain.

22. (Cancelled)

23. (Withdrawn) A method according to claim 9 wherein the immunoconjugate protein forms a dimer of two identical chains, each having ~~an effector~~ said Fc domain of a human IgG1 immunoglobulin and ~~a~~ said targeting domain.

24. (Cancelled)

25. (Cancelled)

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Cancelled)

30. (Cancelled)

31. (Cancelled)

32. (Cancelled)

33. (Cancelled)

34. (Cancelled)

35. (Withdrawn) A method according to claim 9 wherein the disease is rheumatoid arthritis.

36. (Withdrawn) A method according to claim 9 wherein the disease is exudative form of macular degeneration.

37. (Cancelled)

38. (Withdrawn) A method according to claim 9 wherein the disease is atherosclerosis.
39. (Cancelled)
40. (Cancelled)
41. (Cancelled)
42. (Cancelled)
43. (Cancelled)
44. (Cancelled)
45. (Cancelled)
8. ~~46.~~ (Previously presented) An immunoconjugate according to claim 1 wherein the targeting domain of the immunoconjugate protein comprises human factor VII having a substitution of alanine for each of serine-344 and lysine-341.
47. (Cancelled)
48. (Cancelled)
49. (Withdrawn) A method for treating exudative macular degeneration in a patient according to claim 36, wherein the targeting domain comprises native factor VII having a substitution of alanine for lysine-341 and for serine-344.
50. (Cancelled)
51. (Cancelled)
52. (Cancelled)
53. (Cancelled)
9. ~~54.~~ (Previously presented) The immunoconjugate protein according to claim 1 which further comprises a cytotoxic radioactive tag.
10. ~~55.~~ (Currently amended) The immunoconjugate protein of claim 1 wherein the mutant form of ~~human~~ factor VII is native human factor VII having a substitution of alanine for lysine-341.
11. ~~56.~~ (Currently amended) The immunoconjugate protein of claim 1 wherein the mutant form of ~~human~~ factor VII is native human factor VII having a substitution of alanine for serine-344.

12.51. (Currently amended) The immunoconjugate protein of claim 1 wherein the mutant form of ~~human~~ factor VII is native human factor VII having a substitution of alanine for lysine-341 and for serine-344.